Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Highly active anticancer curcumin analogues.

Cara A Mosley1, Dennis C Liotta, James P Snyder

  • 1Department of Chemistry, Emory University, Atlanta, GA 30322, USA. camosle@emory.edu

Advances in Experimental Medicine and Biology
|June 16, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel Competitive, Nonpeptidic, SARS-CoV‑2 M<sup>pro</sup> Inhibitors with Improved Solubility.

ACS medicinal chemistry letters·2026
Same author

Discovery of Novel 2-Morpholine Tetrahydroisoquinoline CXCR4 Antagonists with Unique Properties.

Journal of medicinal chemistry·2026
Same author

Corrigendum to "A subunit-selective negative allosteric modulator of GluN1/GluN3A glycine-activated receptor" [Molecular Pharmacology 108 (2026) 100104].

Molecular pharmacology·2026
Same author

A subunit-selective negative allosteric modulator of GluN1/GluN3A glycine-activated receptor.

Molecular pharmacology·2026
Same author

Discrete interneuron subsets participate in GluN1/GluN3A excitatory glycine receptor (eGlyR)-mediated regulation of hippocampal network activity throughout development and evolution.

bioRxiv : the preprint server for biology·2025
Same author

A 5'-(R)-CH<sub>3</sub>-substituted 5-fluoro-2'-deoxyuridine monophosphate reduces off-target toxicities while maintaining efficacy in a colorectal cancer model.

The Journal of pharmacology and experimental therapeutics·2025
Same journal

Peptidomics in the Spotlight: Advanced Sample Treatment Techniques and Analytical Insights.

Advances in experimental medicine and biology·2026
Same journal

Methods for the Investigation of Protein-Ligands Interactions.

Advances in experimental medicine and biology·2026
Same journal

Sample Preparation Strategies for Microbial Cell Surface Proteomics: Integrating Shaving and Shotgun Approaches.

Advances in experimental medicine and biology·2026
Same journal

Proteomic Sample Preparation for the Petroleum Industry: A Biocorrosion Case Study.

Advances in experimental medicine and biology·2026
Same journal

Proteomic and Functional Comparison of Extracellular Vesicles from Wild-Type and Lyn-Deficient Stromal Cells.

Advances in experimental medicine and biology·2026
Same journal

Proteomic Analysis of Histone Sequence Variants and Post-translationally Modified Forms.

Advances in experimental medicine and biology·2026
See all related articles

Curcumin analogues, particularly monocarbonyl dienones, show potent anti-cancer activity and favorable pharmacokinetics. Targeting these compounds with factor VIIa-tissue factor (fVIIa-TF) enhances efficacy against cancer cells.

Area of Science:

  • Natural Product Chemistry
  • Medicinal Chemistry
  • Cancer Biology

Background:

  • Curcumin, a natural compound, serves as a foundation for developing novel anti-cancer drugs.
  • Structural modifications of curcumin, specifically to monocarbonyl dienones, yield potent cytotoxic agents.
  • These analogues maintain a favorable safety profile, with some exhibiting enhanced oral bioavailability and pharmacokinetics.

Purpose of the Study:

  • To synthesize and evaluate curcumin analogues as potential anti-cancer therapeutics.
  • To investigate the anti-cancer efficacy of modified curcumin structures, including thiol conjugates.
  • To explore the potential of targeting cancer cells using the factor VIIa-tissue factor (fVIIa-TF) pathway.

Main Methods:

  • Synthesis of curcumin analogues, including monocarbonyl dienones and their thiol conjugates.

Related Experiment Videos

  • In vitro evaluation of cytotoxicity against various cancer cell lines.
  • Assessment of pharmacokinetic properties and oral bioavailability in rodent models.
  • Development and testing of a fVIIa-TF targeted protein conjugate (EF24-FFRck-fVIIa).

    • Main Results:

    • Diverse curcumin analogues, especially monocarbonyl dienones, demonstrated significant cytotoxicity against cancer cells.
    • Certain analogues (e.g., EF-24) exhibited good oral bioavailability and pharmacokinetics.
    • Thiol conjugation improved stability and solubility while retaining cellular activity.
    • The EF24-FFRck-fVIIa conjugate showed enhanced efficacy against breast cancer and melanocyte cells.
    • Both simple analogues and the conjugate displayed antiangiogenic activity in cell culture.

    Conclusions:

    • Monocarbonyl dienone curcumin analogues are promising anti-cancer drug candidates.
    • Targeting cancer cells via the fVIIa-TF pathway offers a dual-action strategy for tumor destruction.
    • These modified curcumin compounds and targeted conjugates hold potential for direct tumor apoptosis and antiangiogenesis.